|
1
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States. JAMA.
295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tuttle RM, Ball DW, Byrd D, et al: Thyroid
carcinoma. J Natl Compr Canc Netw. 8:1228–1274. 2010.PubMed/NCBI
|
|
3
|
Veiga LH, Neta G, Aschebrook-Kilfoy B, Ron
E and Devesa SS: Thyroid cancer incidence patterns in Sao Paulo,
Brazil and the US SEER Program. Thyroid. 23:748–757. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang KT and Lee CH: BRAF mutation
in papillary thyroid carcinoma: pathogenic role and clinical
implications. J Chin Med Assoc. 73:113–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mesa C Jr, Mirza M, Mitsutake N, et al:
Conditional activation of RET/PTC3 and BRAFV600E in thyroid
cells is associated with gene expression profiles that predict a
preferential role of BRAF in extracellular matrix
remodeling. Cancer Res. 66:6521–6529. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Durand S, Ferraro-Peyret C, Joufre M,
Chave A, Borson-Chazot F, Selmi-Ruby S and Rousset B: Molecular
characteristics of papillary thyroid carcinomas without BRAF
mutation or RET/PTC rearrangement: relationship with
clinico-pathological features. Endocr Relat Cancer. 16:467–481.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xing M: Genetic alterations in the
phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Thyroid. 20:697–706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Konturek A, Barczynski M, Wierzchowski W,
Stopa M and Nowak W: Coexistence of papillary thyroid cancer with
Hashimoto thyroiditis. Langenbecks Arch Surg. 398:389–394. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou GY, Liu HQ and Zhang QH: Thyroid and
parathyroid gland tumorsDiagnostic Histopathology of Tumors.
Fletcher CD: 1st. Shandong Science and Technology Press; Jinan: pp.
5992001
|
|
10
|
Liao EY and Chao CS: Chronic lymphocytic
thyroiditisEndocrinology. Zhang H, Dai RC and Liao EY: 1st.
People's Medical Publisher; Beijing: pp. 7152001
|
|
11
|
Gouveia C, Can NT, Bostrom A, Grenert JP,
van Zante A and Orloff LA: Lack of association of BRAF
mutation with negative prognostic indicators in papillary thyroid
carcinoma: the University of California, San Francisco, experience.
JAMA Otolaryngol Head Neck Surg. 139:1164–1170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Witt RL, Ferris RL, Pribitkin EA, Sherman
SI, Steward DL and Nikiforov YE: Diagnosis and management of
differentiated thyroid cancer using molecular biology.
Laryngoscope. 123:1059–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu LY, Zhang C, Xu RJ, Zhou H and Ma LZ:
Diagnostic value of TPO, CK-19, Gal-3 and HBME-1 in fine needle
aspiration cytological specimens for thyroid carcinoma with
Hashimoto's disease. Zhejiang Medical. 32:1007–1010. 10132010.
|
|
14
|
Trovisco V, Soares P, Soares R, Magalhães
J, Sa-Couto P and Sobrinho-Simoes M: A new BRAF gene
mutation detected in a case of a solid variant of papillary thyroid
carcinoma. Hum Pathol. 36:694–697. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmidt J, Derr V, Heinrich MC, Crum CP,
Fletcher JA, Corless CL and Nose V: BRAF in papillary
thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol.
31:1337–1343. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lupi C, Giannini R, Ugolini C, et al:
Association of BRAF V600E mutation with poor
clinicopathological outcomes in 500 consecutive cases of papillary
thyroid carcinoma. J Clin Endocrinol Metab. 92:4085–4090. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Frau DV, Lai ML, Caria P, et al: Trisomy
17 as a marker for a subset of noninvasive thyroid nodules with
focal features of papillary carcinoma: cytogenetic and molecular
analysis of 62 cases and correlation with histological findings. J
Clin Endocrinol Metab. 93:177–181. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wolff EF, Hughes M, Merino MJ, Reynolds
JC, Davis JL, Cochran CS and Celi FS: Expression of benign and
malignant thyroid tissue in ovarian teratomas and the importance of
multimodal management as illustrated by a BRAF-positive
follicular variant of papillary thyroid cancer. Thyroid.
20:981–987. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pennelli G, Vianello F, Barollo S, et al:
BRAF (K601E) mutation in a patient with a follicular thyroid
carcinoma. Thyroid. 21:1393–1396. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohori NP, Singhal R, Nikiforova MN, et al:
BRAF mutation detection in indeterminate thyroid cytology
specimens: underlying cytologic, molecular and pathologic
characteristics of papillary thyroid carcinoma. Cancer Cytopathol.
121:197–205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schulten HJ, Salama S, Al-Mansouri Z, et
al: BRAF mutations in thyroid tumors from an ethnically
diverse group. Hered Cancer Clin Pract. 10:10–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Park JY, Kim WY, Hwang TS, et al:
BRAF and RAS mutations in follicular variants of papillary
thyroid carcinoma. Endocr Pathol. 24:69–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim WY, Ko YS and Hwang TS: A case of
multifocal papillary thyroid carcinoma consisting of one
encapsulated follicular variant with BRAF K601E mutation and
three conventional types with BRAF V600E mutation. Korean J
Pathol. 47:293–298. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barollo S, Pezzani R, Cristiani A, et al:
Prevalence, tumorigenic role and biochemical implications of rare
BRAF alterations. Thyroid. 24:809–819. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soares P, Celestino R, Melo M, Fonseca E
and Sobrinho-Simoes M: Prognostic biomarkers in thyroid cancer.
Virchows Archiv. 464:333–346. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roti E, Degli Uberti EC, Bondanelli M and
Braverman LE: Thyroid papillary microcarcinoma: a descriptive and
meta-analysis study. Eur J Endocrinol. 159:659–673. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee X, Gao M, Ji Y, et al: Analysis of
differential BRAF (V600E) mutational status in high
aggressive papillary thyroid microcarcinoma. Ann Surg Oncol.
16:240–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Virk RK, Van Dyke AL, Finkelstein A, et
al: BRAFV600E mutation in papillary thyroid microcarcinoma:
a genotype-phenotype correlation. Mod Pathol. 26:62–70. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim D and Park JW: Clinical implications
of preoperative thyrotropin serum concentrations in patients who
underwent thyroidectomy for nonfunctioning nodule(s). J Korean Surg
Soc. 85:15–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim SK, Song KH, Lim SD, Lim YC, Yoo YB,
Kim JS and Hwang TS: Clinical and pathological features and the
BRAF (V600E) mutation in patients with papillary thyroid
carcinoma with and without concurrent Hashimoto thyroiditis.
Thyroid. 19:137–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
